Kalderos says in a lawsuit that the federal government's 340B contract pharmacy policy is keeping it from effectively marketing its 340B Pay service to let drug companies provide 340B pricing as a post-purchase rebate rather than as a price discount.
Feds Back and Kalderos Resists Pausing Company’s 340B Lawsuit
The federal government told a judge in late December its appeal of her joint ruling in Novartis and United Therapeutics’ (UT) 340B contract pharmacy lawsuits justifies her pausing drug industry vendor Kalderos’ 340B contract pharmacy suit.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
